Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Nephrology Other
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Nephrology Other
    Very Low Birth Weight a Risk Factor for Focal Segmental Glomerulosclerosis - (DGNews)
    Kidney Injury Puts Elders at High Risk for Developing Chronic Kidney Disease - (DGNews)
    Dialysis Patients Have Better Long-Term Survival With Coronary Bypass Than Stents: Presented at ASN - (DGDispatch)
    High Levels of Phosphate Linked to Early Atherosclerosis - (DGNews)
    Preventing Anaemia Is Important in Patients With Chronic Kidney Disease - (DGNews)

    News archive

     Recent webcasts/CME - Nephrology Other
    • Improving the Standard of Care in Acute Hypertension
    • Hydration Protocols to Reduce the Incidence of CIN
      The Acute Cardio-Renal Syndrome: How the Heart and the Kidney Communicate with Each Other
      Drug-Induced Acute Kidney Injury in the ICU
      Pathophysiology of Clinical Disorders of Renal Tubular Electrolyte Reabsorption & Causes of Hypertension vs. Hypotension

      Webcasts/CME archive

       Recent cases - Nephrology Other
        Laparoscopic Pyeloplasty for Ureteropelvic Junction Obstruction of the Lower Moiety in a Completely Duplicated Collecting System: A Case Report
        Membranous Nephropathy in a Patient with Hereditary Angioedema: A Case Report
        Congenital Intrarenal Arteriovenous Malformation Presenting with Gross Hematuria after Endoscopic Intervention: A Case Report
        Bilateral Parapelvic Cysts That Mimic Hydronephrosis in Two Imaging Modalities: A Case Report
        Ultrastructural Pathology of Nephropathies with Organized Deposits: A Case Series

        Cases archive
          




        my personal edition > nephrology other > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Calcium Channel Blockers May Not Add to ACE Inhibition in Nondiabetic Nephropathy: Presented at WCN

        By Paula Moyer

        BERLIN, GERMANY -- June 12, 2003 -- Adding the calcium channel blockers verapamil or amlodipine does not appear to significantly increase the antiproteinuric effect of totrandolapril in patients with nondiabetic nephropathy.

        "Neither verapamil nor amlodipine increased the antiproteinuric effect in patients treated with the [angiotensin-converting enzyme] ACE inhibitor trandolapril," reported Robert Boero, MD, a staff nephrologist at the S.G. Bosco Hospital, in Turin, Italy.

        In addition, Dr. Boero and colleagues found that the combination of trandolapril and verapamil was better tolerated than trandolapril and amlodipine. He presented the findings here June 9th at the World Congress of Nephrology.

        The investigators conducted their study to see whether the combination of the non-dihydropyridine calcium channel blocker verapamil or the dihydropyridine calcium channel blocker amlodipine, when combined with trandolapril, reduced proteinuria more than trandolapril alone in patients with nondiabetic proteinuric nephropathies. They also intended to evaluate the effects of these treatments on the selectivity of proteinuria, such as clearance of immunoglobulin G (IgG) or albumin, and the drugs' safety in these patients.

        The team recruited 49 men and 20 women with nondiabetic nephropathies and an average of 54 years of age. Mean baseline serum creatinine level was 1.9 mg/dL, and mean baseline blood pressure was 136/90 mm Hg.

        Patients went through a 1-month washout period from any ACE inhibitor or any angiotensin receptor blocker. Then they all received 2 mg daily of trandolapril in an open-label fashion for 1 month, after which they were randomly assigned to receive either 180 mg of verapamil or 5 mg of amlodipine daily for 8 months, in a double-blind phase. There were 33 patients in the verapamil arm and 36 in the amlodipine arm.

        After 1 month on trandolapril monotherapy, the mean 24-hour proteinuria level was significantly reduced, from 3,078 mg to 2,537± 204 mg (P=0.005).

        In the randomised phase, the investigators saw still more reduction of proteinuria in both groups, but no differences within and between groups. Patients treated with verapamil had a mean 24-hour proteinuria level of 2,335 mg at the beginning of combination therapy, and 2,124 mg at the end of the study. In the amlodipine group, the proteinuria levels decreased from a mean of 2,715 mg to a mean of 2,671 mg.

        The selectivity of proteinuria was slightly and not significantly reduced in patients treated with the verapamil combination, from a median of 0.20 to a median of 0.16. In amlodipine-treated patients, this parameter significantly increased from a median of 0.20 to a median of 0.30 (P=0.0001). After randomisation, the verapamil group's serum creatinine level increased from 1.8 mg/dL to 1.9 mg/dL, a change the investigators did not find statistically significant. In the amlodipine group, that level increased from 2.2 mg/dL to 2.5 mg/dL (P=0.001).

        In the overall patient group, the investigators found the changes in selectivity of proteinuria and serum creatinine from randomisation to the end of the study to be significantly and directly correlated (r=0.45, P=0.001).

        Blood pressure levels at the end of the study were 127/83 mm Hg in the verapamil group and 125/83 mm Hg in the amlodipine group, a difference the investigators did not find to be statistically significant.

        In the amlodipine group, 63.8% of patients reported adverse effects that the researchers considered to be related to this medication; in the verapamil group, the adverse events rate was 33.3% (P=0.016).

        The researchers concluded that these findings show that neither verapamil nor amlodipine significantly adds any benefit to trandolapril's antiproteinuric effect. Dr. Boero urged further study to determine the possibility that amlodipine has an adverse effect of the selectivity of proteinuria and on renal function.


        [Study title: The VVAMMTT Study: Verapamil Versus Amlodipine In Nondiabetic Nephropathies Treated With Trandolapril. Abstract M250]




        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send